INmune Bio (NASDAQ:INMB) Trading 1.7% Higher - What's Next?

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) shares were up 1.7% during mid-day trading on Tuesday . The stock traded as high as $4.93 and last traded at $4.88. Approximately 131,907 shares changed hands during mid-day trading, a decline of 20% from the average daily volume of 165,580 shares. The stock had previously closed at $4.80.

Wall Street Analysts Forecast Growth

INMB has been the subject of several research reports. Alliance Global Partners began coverage on INmune Bio in a research note on Monday, October 21st. They set a "buy" rating and a $20.00 price target for the company. Raymond James started coverage on shares of INmune Bio in a research report on Friday, September 27th. They set an "outperform" rating and a $18.00 target price for the company. Finally, Scotiabank initiated coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They issued a "sector outperform" rating and a $22.00 price target on the stock.

INmune Bio Price Performance

The stock has a market capitalization of $108.41 million, a P/E ratio of -2.24 and a beta of 1.85. The stock has a fifty day moving average price of $5.36 and a 200 day moving average price of $7.14.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same period in the prior year, the business earned ($0.48) earnings per share. Research analysts anticipate that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

Insider Buying and Selling

In other INmune Bio news, CEO Raymond Joseph Tesi purchased 15,380 shares of the stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, with a total value of $98,124.40. Following the completion of the purchase, the chief executive officer now directly owns 1,554,106 shares of the company's stock, valued at approximately $9,915,196.28. This trade represents a 1.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO David J. Moss acquired 10,000 shares of INmune Bio stock in a transaction dated Monday, September 30th. The shares were bought at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the completion of the purchase, the chief financial officer now directly owns 1,285,869 shares of the company's stock, valued at approximately $6,802,247.01. The trade was a 0.78 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 33,070 shares of company stock worth $200,087. Corporate insiders own 35.20% of the company's stock.

Institutional Investors Weigh In On INmune Bio

Several institutional investors have recently bought and sold shares of INMB. Financial Advocates Investment Management increased its position in shares of INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company's stock valued at $73,000 after acquiring an additional 2,000 shares during the period. Jane Street Group LLC purchased a new position in INmune Bio during the 3rd quarter valued at about $79,000. Sanctuary Advisors LLC bought a new position in INmune Bio during the 3rd quarter valued at approximately $113,000. Rhumbline Advisers purchased a new stake in INmune Bio in the 2nd quarter worth approximately $121,000. Finally, Barclays PLC lifted its holdings in INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company's stock worth $157,000 after buying an additional 24,906 shares during the period. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.